KIF5B-RET fusions in Chinese patients with non-small cell lung cancer

Cancer

Volumn 119, Issue 8, 2013, Pages 1486-1494

  Cai, Weijing ^a   Su, Chunxia ^a   Li, Xuefei ^a   Fan, Lihong ^a   Zheng, Limou ^b   Fei, Ke ^a   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b XIAMEN UNIVERSITY   (China)

Author keywords

fusion; KIF5B RET; non small cell lung cancer; oncogenic driver; rearrangement

Indexed keywords

KINESIN; KINESIN FAMILY MEMBER 5B PROTEIN; PROTEIN RET; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FUSION GENE; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIF5B RET FUSION GENE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLEX REAL TIME POLYMERASE CHAIN REACTION; NEUROENDOCRINE TUMOR; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEX DIFFERENCE; SMOKING; SURVIVAL TIME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KINESIN; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; REAL-TIME POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 84876033073     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27940     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-566.
3. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol. 2009; 40: 1152-1158.
4. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009; 115: 1723-1733.
5. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
6. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012; 30: 863-870.
7. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012; 18: 375-377.
8. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012; 18: 382-384.
9. Li F, Feng Y, Fang R, et al. Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. Cell Res. 2012; 22: 928-931.
10. Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012; 22: 436-445.
11. Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012; 18: 4570-4579.
12. Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement [abstract]. J Clin Oncol. 2012 (30S). Abstract 7508.
13. Baloh RH, Enomoto H, Johnson EM Jr, Milbrandt J,. The GDNF family ligands and receptors-implications for neural development. Curr Opin Neurobiol. 2000; 10: 103-110.
14. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990; 60: 557-563.
15. Fugazzola L, Pilotti S, Pinchera A, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res. 1995; 55: 5617-5620.
16. Jhiang SM, Sagartz JE, Tong Q, et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology. 1996; 137: 375-378.
17. Murakumo Y, Jijiwa M, Asai N, Ichihara M, Takahashi M,. RET and neuroendocrine tumors. Pituitary. 2006; 9: 179-192.
18. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer; Nat Med. 2012; 18: 378-381.
19. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27: 4247-4253.
20. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010; 17: 889-897.
21. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008; 14: 4275-4283.
22. Govindan R, Hammerman PS, Hayes DN, et al. Comprehensive genomic characterization of squamous cell carcinoma of the lung [abstract]. J Clin Oncol. 2012 (30S). Abstract 7006.
23. Comis RL,. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Oncologist. 2005; 10: 467-470.
24. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993; 363: 458-460.
25. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993; 2: 851-856.
26. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994; 367: 375-376.
27. Oberg K, Hellman P, Kwekkeboom D, Jelic S,. Neuroendocrine bronchial and thymic tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 (suppl 5): 220-222.
28. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiology, and End Results database. J Clin Oncol. 2006; 24: 4539-4544.
29. Navada S, Lai P, Schwartz A, Kalemkerian G,. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End Results (SEER) database [abstract]. J Clin Oncol. 2006; 24 (18S). Abstract 7082.
30. Travis W, Brambilla E, Muller-Hermelink H, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
31. Bajetta E, Catena L, Procopio G, et al. Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol. 2005; 16: 1374-1380.
32. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM,. Bronchopulmonary neuroendocrine tumors. Cancer. 2008; 113: 5-21.
33. Moertel CG, Kvols LK, O'Connell MJ, Rubin J,. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991; 68: 227-232.